Prof. Ernst Wagner Joins Coriolis Pharma’s Scientific Advisory Board as Expert for Nucleic Acid Therapeutics

Coriolis Pharma, a globally operating service provider and one of the world leaders in formulation research and development of (bio)pharmaceutical drugs, today announced that Prof. Dr. Ernst Wagner has joined its scientific advisory board. Prof. Wagner’s distinguished expertise with nucleic acids and gene delivery perfectly fits to the services offered by Coriolis Pharma and strengthens Coriolis’ scientific expertise in the field of advanced therapy medicinal products (ATMPs).

“We are very pleased to welcome Ernst to our scientific advisory board,“ said Dr. Michael Wiggenhorn, CEO of Coriolis Pharma. “His distinguished expertise about nucleic acids and gene delivery will be of high value to our client projects, particularly in the booming field of advanced therapy medicinal products. Ernst will actively be involved in project discussions and will contribute with his long-year experience to successful project outcomes.”

Prof. Wagner is a professor of Pharmaceutical Biotechnology at the Ludwig-Maximilians-Universität (LMU) and the Center of Nanoscience in Munich, Germany. Previously (1991-2001), he was the Director Cancer Vaccines & Gene Therapy at Boehringer Ingelheim in Vienna, Austria, where he supervised the first-in-world polymer-based human gene therapy trial in 1994. Prof. Wagner is an Academician of European Academy of Sciences, a member of the Controlled Release Society (CRS) College of Fellows, a board member of German Society for Gene Therapy, and the Editor-in-Chief of the Journal of Gene Medicine.

Prof. Wagner has authored more than 475 publications with almost 45 000 citations. His current academic reseach projects focus on the targeted delivery of nucleic acids (including mRNA) and protein therapeutics.

“Ernst’s research interest also fits perfectly to the scope of our internal research unit,” explains Dr. Andrea Hawe, CSO of Coriolis Pharma. “We are looking forward to collaborative research projects and joint publications in the exciting field of gene and cell therapy. This will be of direct benefit to our clients, because we always apply the gained knowledge from our research projects to improve the services for our clients.”

“It is a pleasure and honor for me to support Coriolis Pharma as company originating from the LMU, after having followed their scientifically driven great success during the last years,” comments Prof. Wagner his move towards Coriolis.

Coriolis’ Scientific Advisory Board includes:

• Dr. Gerhard Winter, Department of Pharmaceutical Technology and Biopharmaceutics, LMU Munich

• Dr. Wolfgang Frieß, Department of Pharmaceutical Technology and Biopharmaceutics, LMU Munich

• Dr. Wim Jiskoot, Leiden Academic Centre for Drug Research, Leiden University, The Netherlands

• Dr. Christian Schöneich, Department of Pharmaceutical Chemistry, University of Kansas, USA

• Dr. Gideon Kersten, Leiden Academic Centre for Drug Research, Leiden University, The Netherlands

• Dr. Ernst Wagner, Department of Pharmaceutical Biotechnology, LMU Munich

About Coriolis Pharma

Coriolis Pharma is a globally operating service provider and one of the world leaders in formulation research and development of (bio)pharmaceutical drugs including proteins, peptides, monoclonal antibodies, nucleic acids, virus-like particles, vaccines, advanced therapy medicinal products (ATMPs) and genetically modified organisms (GMOs). Coriolis Pharma develops liquid and lyophilized formulations out of one hand with all technologies and analytical methods in-house. For each individual project, highly skilled scientists develop tailor-made study designs that align with the clients’ drug development strategy. With science-driven innovative solutions, Coriolis Pharma support all phases of drug development including troubleshooting, batch-release testing including innovative methods and formulation optimization even beyond market approval. Our mission is: formulating innovation!